事件:?2025 年9 月22 日,迈威生物、英硅智能、皓元医药三方共同宣布正式达成战略合作协议。此次合作的核心目标是协力打造一个覆盖数百个靶点的新型ADC(抗体偶联药物)化合物库,并基于该库进行候选分子的筛选与开发,以加速下一代创新ADC 药物的产业化进程。ADC 药物被誉为“生物导弹”,是当前全球肿瘤治疗领域最具前景的研发方向之一。投资要点:?强强联合,优势互补构建核心竞争力。本次合作集结了各...
Source Link事件:?2025 年9 月22 日,迈威生物、英硅智能、皓元医药三方共同宣布正式达成战略合作协议。此次合作的核心目标是协力打造一个覆盖数百个靶点的新型ADC(抗体偶联药物)化合物库,并基于该库进行候选分子的筛选与开发,以加速下一代创新ADC 药物的产业化进程。ADC 药物被誉为“生物导弹”,是当前全球肿瘤治疗领域最具前景的研发方向之一。投资要点:?强强联合,优势互补构建核心竞争力。本次合作集结了各...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.